Literature DB >> 23721604

S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version.

Annette Pflugfelder1, Corinna Kochs, Andreas Blum, Marcus Capellaro, Christina Czeschik, Therese Dettenborn, Dorothee Dill, Edgar Dippel, Thomas Eigentler, Petra Feyer, Markus Follmann, Bernhard Frerich, Maria-Katharina Ganten, Jan Gärtner, Ralf Gutzmer, Jessica Hassel, Axel Hauschild, Peter Hohenberger, Jutta Hübner, Martin Kaatz, Ulrich R Kleeberg, Oliver Kölbl, Rolf-Dieter Kortmann, Albrecht Krause-Bergmann, Peter Kurschat, Ulrike Leiter, Hartmut Link, Carmen Loquai, Christoph Löser, Andreas Mackensen, Friedegund Meier, Peter Mohr, Matthias Möhrle, Dorothee Nashan, Sven Reske, Christian Rose, Christian Sander, Imke Satzger, Meinhard Schiller, Heinz-Peter Schlemmer, Gerhard Strittmatter, Cord Sunderkötter, Lothar Swoboda, Uwe Trefzer, Raymond Voltz, Dirk Vordermark, Michael Weichenthal, Andreas Werner, Simone Wesselmann, Ansgar J Weyergraf, Wolfgang Wick, Claus Garbe, Dirk Schadendorf.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23721604     DOI: 10.1111/ddg.12044

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  13 in total

Review 1.  Follow-up in patients with low-risk cutaneous melanoma: is it worth it?

Authors:  Ulrike Leiter; Thomas Eigentler; Claus Garbe
Journal:  Melanoma Manag       Date:  2014-12-04

Review 2.  Ipilimumab for the treatment of melanoma.

Authors:  Shikha Jain; Joseph I Clark
Journal:  Melanoma Manag       Date:  2015-02-25

3.  [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].

Authors:  C Pfannenberg; N Schwenzer
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

4.  Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?

Authors:  Benedikt Michael Schaarschmidt; Johannes Grueneisen; Vanessa Stebner; Joachim Klode; Ingo Stoffels; Lale Umutlu; Dirk Schadendorf; Philipp Heusch; Gerald Antoch; Thorsten Dirk Pöppel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

5.  Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience.

Authors:  Vidhya Karivedu; Ihab Eldessouki; Ahmad Taftaf; Zheng Zhu; Abouelmagd Makramalla; Nagla Abdel Karim
Journal:  Case Rep Oncol Med       Date:  2019-04-17

Review 6.  Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.

Authors:  Amy A Mrazek; Celia Chao
Journal:  Surg Clin North Am       Date:  2014-08-05       Impact factor: 2.741

Review 7.  Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives.

Authors:  Kristina Buder; Anja Gesierich; Götz Gelbrich; Matthias Goebeler
Journal:  Cancer Med       Date:  2013-09-18       Impact factor: 4.452

8.  Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma.

Authors:  Tarun Mehra; Gerd Grözinger; Steven Mann; Emmanuella Guenova; Rudolf Moos; Martin Röcken; Claus Detlef Claussen; Reinhard Dummer; Stephan Clasen; Aline Naumann; Claus Garbe
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

9.  Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma.

Authors:  Wei-Yin Lim; Robin M Turner; Rachael L Morton; Marisa C Jenkins; Les Irwig; Angela C Webster; Mbathio Dieng; Robyn P M Saw; Pascale Guitera; Donald Low; Cynthia Low; Katy J L Bell
Journal:  BMC Health Serv Res       Date:  2018-06-20       Impact factor: 2.655

10.  Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients.

Authors:  Lutz Kretschmer; Hans Peter Bertsch; Antonia Zapf; Christina Mitteldorf; Imke Satzger; Kai-Martin Thoms; Bernward Völker; Michael Peter Schön; Ralf Gutzmer; Hans Starz
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.